

## HIV Diagnosis Following Discharge from Psychiatric Hospitalization: A Claims-Based, Real-World Study

#### Samuel R. Bunting, MD, MS,1\* Max Hyman, BS,2 & Aniruddha Hazra, MD3,4

1. Department of Psychiatry and Behavioral Neuroscience, University of Chicago Medicine, Chicago, IL, USA; samuel.bunting@bsd.uchicago.edu

492.363 unique enrollees included in cohort

and those who were not married (84.8%)

Most common reason for hospitalization was depression

• Average length of hospitalization of 6.35 (SD = 7.36) days

· 277 new HIV diagnoses identified during follow-up period

New HIV diagnoses were more common among males (67.1%)

• Most new HIV were diagnoses in the Western U.S. (39.7%)

n

32,218

62,709

191,105

26 228

8,601

2,580

168,645

228.809

263,277

341,610

150,476

76.154

131 974

201,687

78,550

3.721

М

33.3

6.35

4. Centers for Disease Control & Prevention. HIV Surveillance Data Tables. 2023

6. The White House. National HIV/AIDS Strategy for the United States 2022-2025. 2021

https://www.cdc.gov/hiv/policies/dear-colleague/dcl/20231017.htm

Drug Use. JAMA Netw Open. Jul 1 2022;5(7):e2221346.

Training Program (5R25MH083620)

Sample

%

6.54%

12.7%

38.8%

5 33%

1.75%

0.52%

34.3%

46.5%

53.5%

69.4%

30.6%

15.5%

26.8%

41.0%

16.0%

0.76%

SD

15.4

7.36

a. Psychotic disorders included schizophrenia, schizoaffective disorder(s), substance-induced psychosis, and

1. Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in

Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA. Jan 3

5. Drallmeier T, Garrett EK, Meyr A, Salas J, Scherrer JF. Demographic factors, psychiatric and physical

comorbidities associated with starting preexposure prophylaxis in a nationally distributed cohort. Prev Med. Nov 2022;164:107344.

Streed CG, Jr., Morgan JR, Gai MJ, Larochelle MR, Paasche-Orlow MK, Taylor JL, Prevalence of HIV

**Acknowledgements & Disclosures** 

· Project funded by Gilead Sciences via independent investigator award paid directly to University

of Chicago, Additional support from the Brown University Community and Clinical Research

Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection

people with severe mental illness: a systematic review and meta-analysis. The Lancet Psychiatry. 2016;3(1):40-48.

2. McGinty EE, Presskreischer R, Breslau J, et al. Improving Physical Health Among People With Serious

Mental Illness: The Role of the Specialty Mental Health Sector. Psychiatr Serv. Nov 1 2021;72(11):1301-

Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in

References

**HIV Diagnosis** 

%

11.9%

11.6%

39.0%

4 69%

1.81%

2.89%

28.2%

67 1%

32.9%

84.8%

15.2%

21.7%

19.5%

39.7%

18.8%

0.36%

SD

13.2

6.33

n

33

32

108

13

5

8

78

186

91

235

42

60

54

110

52

1 M

31.6

6.34

2. Center for Health and the Social Sciences, University of Chicago, Chicago, IL, USA

(38.8%)

3. Chicago Center for HIV Elimination, University of Chicago Medicine, Chicago, IL, USA

(after discharge)

Reason for Admission

Alcohol Use Disorder

Bipolar Disorder

Depression

Opioid Use Disorder

Stimulant Use Disorder

Other

Male

Female

No

Yes

Northeast

N Central

West

South

Unknown

Age (years)

Length of Stay (days)

unspecified psychosis

2023;329(1):63-84

1310

Sex

Married

Region

Psychotic Disorde

4. Section of Infectious Disease and Global Health, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA

• Mean age: 33.3 (SD = 15.4) years

#### Background


- People living with mental illnesses (PLWMI) experience disproportionate HIV incidence<sup>1</sup>
- HIV contributes to excess morbidity and early mortality among PLWMI, who experience up to 25 yr. shorter life expectancy<sup>2</sup>
- Daily antiretroviral medication as HIV pre-exposure prophylaxis (PrEP) up to 99% effective<sup>3</sup>
- Effective, biomedical HIV prevention options are effective and remain under-utilized for all patients in the U.S. (~36% of patients with PrEP indication were actually prescribed in 2022)<sup>4</sup>
- PrEP use among PLWMI is poorly understood, however limited work suggests < 1% of people with bipolar disorder and schizophrenia were prescribed PrEP between 2013-2018, despite well-documented HIV vulnerability<sup>5</sup>
- National policy agendas highlight the 'no wrong door' approach to integration of HIV prevention and mental health/substance use treatment<sup>6</sup>
- Minimal research has investigated opportunities for HIV prevention care or the unique needs of PLWMI for HIV prevention in the healthcare system

#### Methods

- Retrospective study using the MarketScan® commercial claims database of fully-adjudicated medical and pharmacy claims for privately insured Americans
- Data years 2004-2022, representing approximately 151 million unique enrollees; Cohort entry at any year
- Index date (inclusion in cohort): Day of discharge claim + 1
- Follow up period: 365 days after index date
- · Inclusion criteria:
  - Hospital admission claim (inpatient) with a psychiatric diagnosis related group (DRG) or psychiatric diagnosis as primary diagnosis for admission
  - Age ≥ 14 years old
  - At least one year of continuous coverage prior to and after index date
- Exclusion criteria:
  - Any claims with HIV-related diagnosis code prior to hospitalization
  - 28-30 days of HIV treatment regimen; single 28/30-day prescription assumed post-exposure prophylaxis (PEP)
- Primary Outcome: New HIV diagnosis in follow-up period
  - Defined as: Date of second outpatient claim or first inpatient claim with HIV diagnosis code *or* ≥31 days of antiretrovirals for HIV treatment

### Results

- Median time of 154 (IQR: 61-243) days (5.1 months) to new HIV diagnosis following discharge from psychiatric hospitalization
- Longest median time to HIV diagnosis was identified for people hospitalized for depression (170.5 days [IQR: 76.5-266])
- Shortest median time to HIV identified among people hospitalized primarily for stimulant use disorder (40 days [IQR:32-69.5])



Mean number of days to new HIV diagnosis following discharge from psychiatric hospitalization, grouped by the primary diagnosis at the time of admission. Diamonds indicate median number of days to HIV diagnosis following discharge. Psychotic disorders included schizophrenia, schizoaffective disorder(s), substance-induced psychosis, and unspecified psychosis.

#### **Conclusions & Future Directions**

- Psychiatric illness and symptoms are broadly associated with increased incidence of HIV
- Psychiatric hospitals often function as a safety-net for PLWMI who are not well-engaged with the healthcare system or who are experiencing acute psychiatric care needs
- Using a conservative approach, we identified 277 new HIV diagnoses following psychiatric hospitalization, and median time to diagnosis for all was < 6 months after discharge</li>
- Psychiatric hospitals may serve as an efficient point of integration for HIV screening, preventive counseling, and coordination of PrEP care
- Stimulant use disorder as a particularly important diagnosis to prioritize for intervention, previous work with similar data finding < 1% using PrEP<sup>7</sup>
- These data may serve as a foundation for larger studies to identify patients in psychiatric and substance use care who may benefit from PrEP and other HIV prevention interventions within psychiatric care
- Further research is needed to understand gaps in PrEP care for PLWMI including in a larger sample with all insurers

# The Chicago Study for HIV Prevention in Psychiatry\*\*\*